REFERENCES

1. Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause.

2. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implica­tions for forecasting menopause. Hum Reprod 1992;7:1342-46.

3. Tarlatzis BC, Zepiridis L. Perimenopausal conception. Ann N T Acad Sci 2003;997:93-104.

4. Hook EB, Cross PK, Schreinemachers DM. Chromosomal ab­normality rates at amniocentesis and in live-born infants. JAMA 1983;249:2034-48.

5. Loane M, Morris JK, Addor MC, Arriola L, Budd J, Doray B, et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur JHum Genet 2013;21:27-33.

6. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387-402.

7. Office for National Statistics, UK. Statistical Bulletin for Births in England and Wales. 2013. Available at: http://www.ons.gov.uk/ons/ dcp171778_371129.pdf.

8. Human Fertilisation and Embryology Authority. Fertility treat­ment in 2013. Available at: http://www.hfea.gov.uk/docs/HFEA_ Fertility_Trends_and_Figures_2013.pdf.

9. Friedman D. Perk up: Facebook and Apple now pay for women to freeze eggs. NBC News; 2014. Available at: http:// www.nbcnews.com/news/us-news/perk-facebook-apple-now- pay-women-freeze-eggs-n225011.

10. Kim SY, Dietz PM, England L, Morrow B, Callaghan WM. Trends in pre-pregnancy obesity in nine states, 1993-2003. Obesity (Silver Spring) 2007;15:986-93.

11. McCartney CR, Blank SK, Prendergast KA, et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls.

12. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update 2003;9:359-72.

13. Greisen S, Ledet T, Moller N, et al. Effects of leptin on basal and FSH stimulated steroidogenesis in human granulosa luteal cells. Acta Obstet Gynecol Scand 2000;79:931-35.

14. Kjsr MM, Nilas L. Timing of pregnancy after gastric bypass-a na­tional register-based cohort study. Obes Surg 2013;23:1281-85.

15. Manning S, Finer N, Elkalaawy M, et al. Timing of pregnancy in obese women after bariatric surgery. Pregnancy Hypertens 2014;4:235.

16. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 105: bariatric surgery and pregnancy. Obstet Gynecol 2009;113:1405-13.

17. Magdaleno R, Pereira BG, Chaim EA, Turato ER. Pregnancy after bariatric surgery: a current view of maternal, obstetrical and peri­natal challenges. Arch Gynecol Obstet 2012;285:559-66.

18. Shah DK, Ginsburg ES. Bariatric surgery and fertility. Curr Opin Obstet Gynecol 2010;22:248-54.

19. Marceau P, Kaufman D, Biron S, et al. Outcome of pregnancies after biliopancreatic diversion. Obes Surg 2004;14:318-24.

20. Kitzmiller JL, Wallerstein R, Correa A, Kwan S. Preconception care for women with diabetes and prevention of major congenital mal­formations. Birth Defects Res A Clin Mol Teratol 2010;88:791-803.

21. Evers IM, de Valk HW, Visser GH. Risk of complications of preg­nancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 2004;328:915.

22. Persson M, Norman M, Hanson U. Obstetric and perinatal out­comes in type 1 diabetic pregnancies: a large, population-based study. Diabetes Care 2009;32:2005-2009.

23. Jensen DM, Korsholm L, Ovesen P, Beck-Nielsen H, Moelsted- Pedersen L, Westergaard JG, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 2009;32:1046-48.

24.

25. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb con­centration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care 2007;30:1920-25.

26. Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol 2005;105:239-45.

27. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid defi­ciency during pregnancy and subsequent neuropsychological de­velopment of the child. V Engl J Med 1999;341:549-55.

28. Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol 1993;81:349-53.

29. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2543-65.

30. Ferrer RL, Sibai BM, Mulrow CD, Chiquette E, Stevens KR, Cornell J. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 2000;96:849-60.

31. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014;2:CD002252.

32. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major con­genital malformations after first-trimester exposure to ACE in­hibitors. N Engl J Med 2006;354:2443-51.

33. Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014;160:695-703.

34. Roos-Hesselink JW, Ruys TP, Stein JI, et al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology.

35. Opotowsky AR, Siddiqi OK, D’Souza B, Webb GD, Fernandes SM, Landzberg MJ. Maternal cardiovascular events during childbirth among women with congenital heart disease. Heart 2012;98:145-51.

36. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147-97.

37. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122-40.

38. Castellano JM, Narayan RL, Vaishnava P, Fuster V Anticoagulation during pregnancy in patients with a prosthetic heart valve. Nat Rev Cardiol 2012;9:415-24.

39. Hung L, Rahimtoola SH. Prosthetic heart valves and pregnancy. Circulation 2003;107:1240-46.

40. Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 2001;37:893-99.

41. Elbaz G, Fich A, Levy A, Holcberg G, Sheiner E. Inflammatory bowel disease and preterm delivery. Int J Gynaecol Obstet 2005;90:193-97.

42. Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Complications from inflammatory bowel disease during preg­nancy and delivery. Clin Gastroenterol Hepatol 2012;10:1246-52.

43. Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol 2002;97:641-48.

44. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004;15:237-41.

45. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and man­agement of Crohn’s disease: special situations. J Crohns Colitis 2010;4:63-101.

46. Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of dis­ease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease.

47. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17.

48. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99:443-46.

49. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993;105:1057-60.

50. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54.

51. Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic review of effects ofwithdrawal ofimmunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 2015;149:1716-30.

52. Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016;150:734-57.

53. Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NA. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997;58:229-37.

54. Khosla R, Willoughby CP, Jewell DP. Crohn’s disease and preg­nancy. Gut 1984;25:52-56.

55. 0rding Olsen K, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during dis­ease, and after surgery compared with a population sample. Gastroenterology 2002;122:15-19.

56. Woolfson K, Cohen Z, McLeod RS. Crohn’s disease and preg­nancy. Dis Colon Rectum 1990;33:869-73.

57. Anderson BT, Ertle JT, Borum ML. Men with inflammatory bowel disease are rarely counseled regarding effects of immuno­suppressive therapy on fertility and pregnancy. J Crohns Colitis 2013;7:e716.

58. Narendranathan M, Sandler RS, Suchindran CM, Savitz DA. Male infertility in inflammatory bowel disease. J Clin Gastroenterol 1989;11:403-406.

59. Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981;22:445-51.

60. Powell HR, Ekert H. Methotrexate-induced congenital malforma­tions. Med J Aust 1971;2:1076-77.

61. Bruce A, Black M, Bhattacharya S. Mode of delivery and risk of inflammatory bowel disease in the offspring: systematic review and meta-analysis of observational studies. Inflamm Bowel Dis 2014;20:1217-26.

62. Grouin A, Brochard C, Siproudhis L, et al. Perianal Crohn’s dis­ease results in fewer pregnancies but is not exacerbated by vaginal delivery. Dig Liver Dis 2015;47:1021-26.

63. Smink M, Lotgering FK, Albers L, de Jong DJ. Effect of childbirth on the course of Crohn’s disease; results from a retrospective co­hort study in the Netherlands. BMC Gastroenterol 2011; 11:6.

64. Practice parameter: management issues for women with epi­lepsy (summary statement). Report of the Quality Standards Subcommittee ofthe American Academy of Neurology. Neurology 1998;51:944-48.

65. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Practice Parameter update: Management issues for women with epilepsy—F ocus on pregnancy (an evidence-based re­view): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee ofthe American Academy of Neurology and American Epilepsy Society. Neurology 2009;73:133-41.

66. Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malfor­mations. Epilepsy Res 1991;8:75-78.

67. [No authors listed.] Appendix C: AAN summary of evidence­based guideline for clinicians: management issues for women with epilepsy-focus on pregnancy: vitamin k, folic acid, blood levels, and breastfeeding. Continuum (Minneap Minn) 2016;22:285-86.

68. Alonso A, Hernan MA. Temporal trends in the incidence of mul­tiple sclerosis: a systematic review. Neurology 2008;71:129-35.

69. Ramagopalan SV, Sadovnick AD. Epidemiology of multiple sclerosis. Neurol Clin 2011;29:207-17.

70. Finkelsztejn A, Brooks JB, Paschoal FM, Fragoso YD. What can we really tell women with multiple sclerosis regarding preg­nancy? A systematic review and meta-analysis of the literature. BJOG 2011;118:790-97.

71. Confavreux C, Hutchinson M, Hours MM, Cortinovis- Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285-91.

72. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and mul­tiple sclerosis (the PRIMS study): clinical predictors of post­partum relapse. Brain 2004;127:1353-60.

73. Coyle PK. Multiple sclerosis and pregnancy prescriptions. Expert Opin Drug Saf 2014;13:1565-68.

74. Lockwood CJ, Rand JH. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv 1994;49:432-41.

75. Lockwood CJ. Inherited thrombophilias in pregnant patients: de­tection and treatment paradigm. Obstet Gynecol 2002;99:333-41.

76. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum pe­riod: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311-15.

77. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in preg­nancy: a systematic review. Br J Haematol 2006;132:171-96.

78. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-29.

79. Burns DN, Landesman S, Muenz LR, et al. Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr 1994;7:718-26.

80. Turner BJ, Hauck WW, Fanning TR, Markson LE. Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:327-37.

81. Kalish LA, Boyer K, Brown G, et al. Cigarette smoking and maternal-child HIV transmission. Women and Infants Transmission Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:86-89.

82. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-t o-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22:973-81.

83. Study EC. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-65.

84. Anglemyer A, Rutherford GW, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmis­sion in HIV-discordant couples. Cochrane Database Syst Rev 2011;8:CD009153.

85. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shed­ding in Cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003;17:2169-76.

86. Semprini AE, Levi-Setti P, Bozzo M, et al. Insemination of HIV­negative women with processed semen of HIV-positive partners. Lancet 1992;340:1317-19.

87. Manktelow BN, Smith LK, Evans TAA, et al. Perinatal Mortality Surveillance Report: UK Perinatal Deaths for Births from January to December 2013. Leicester: The Infant Mortality and Morbidity Group, Department of Health Sciences, University ofLeicester; 2015.

88. Royal College of Obstetricians and Gynaecologists (RCOG). Registration of Stillbirths and Certification for Pregnancy Loss Before 24 Weeks of Gestation. Good Practice Guideline No. 4. London: RCOG; 2005. Available at: https://www.rcog.org.uk/ en/guidelines-research-services/guidelines/good-practice-4/.

89. Royal College of Obstetricians and Gynaecologists (RCOG). Late Intrauterine Fetal Death and Stillbirth. Green-top Guideline No. 55. London: RCOG; 2010. Available at: https://www.rcog.org.uk/ en/guidelines-research-services/guidelines/gtg55/.

90. Black M, Shetty A, Bhattacharya S. Obstetric outcomes sub­sequent to intrauterine death in the first pregnancy. BJOG 2008;115:269-74.

91. Robson S, Chan A, Keane RJ, Luke CG. Subsequent birth out­comes after an unexplained stillbirth: preliminary population­based retrospective cohort study. Aust N Z J Obstet Gynaecol 2001;41:29-35.

92. Sharma PP, Salihu HM, Kirby RS. Stillbirth recurrence in a popu­lation of relatively low-risk mothers. Paediatr Perinat Epidemiol 2007;21 Suppl 1:24-30.

93. Silver RM. Fetal death. Obstet Gynecol 2007;109:153-67.

94. Korteweg FJ, Erwich JJ, Holm JP, et al. Diverse placental path­ologies as the main causes of fetal death. Obstet Gynecol 2009;114:809-17.

95. Group SCRNW Causes of death among stillbirths. JAMA 2011;306:2459-68.

96. Yudkin PL, Wood L, Redman CW. Risk of unexplained stillbirth at different gestational ages. Lancet 1987;1:1192-94.

97. Caughey AB, Musci TJ. Complications of term pregnancies be­yond 37 weeks of gestation. Obstet Gynecol 2004;103:57-62.

98. Won RH, Currier RJ, Lorey F, Towner DR. The timing of de­mise in fetuses with trisomy 21 and trisomy 18. Prenat Diagn 2005;25:608-11.

99. Bhutta ZA, Yakoob MY, Lawn JE, et al. Stillbirths: what difference can we make and at what cost? Lancet 2011;377:1523-38.

100. Goldenberg RL, McClure EM, Saleem S, Reddy UM. Infection- related stillbirths. Lancet 2010;375:1482-90.

101. Office for National Statistics. Childhood, infant and perinatal mortality in England and Wales, 2013. 2015. Available at: https:// www.ons.gov.uk / peoplepopulationandcommunity/ birthsdeathsandmarriages/ deaths/bulletins/childhood- infantandperinatalmortalityinenglandandwales/2015-03-10.

102. US Department of Health Education, and Welfare. The United States and Six West European Countries. Washington DC: National Centre for Health Statistics; 1967.

103. Sharpe C, Kuschel C. Outcomes of infants born to mothers re­ceiving methadone for pain management in pregnancy. Arch Dis Child Fetal Neonatal Ed 2004;89:F33-6.

104. Larson JD, Patatanian E, Miner PB, Rayburn WF, Robinson MG. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol 1997;90:83-87.

105. Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541-45.

106. Charache S, Condit PT, Humphreys SR. Studies on the folic acid vitamins. IV The persistence of amethopterin in mammalian tis­sues. Cancer 1960;13:236-40.

107. Food and Drug Administration. Federal Register. Available at: https://www.federalregister.gov/index/2018/ food-and-drug-administration.

108. Department of Health and Human Services, Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. 2014. Available at: https:// www.fda.gov/downloads/aboutfda/reportsmanualsforms/ reports/economicanalyses/ucm427798.pdf.

109. McCandlish R, Bowler U, van Asten H, et al. A randomised con­trolled trial of care of the perineum during second stage of normal labour. Br J Obstet Gynaecol 1998;105:1262-72.

110. Fernando RJ, Williams AA, Adams EJ. The Management of Third and Fourth Degree Perineal Tears. Green-top Guideline No. 29. London: RCOG; 2007.

111. Haadem K, Dahlstrom JA, Ling L, Ohrlander S. Anal sphincter function after delivery rupture. Obstet Gynecol 1987; 70:53-56.

112. Haadem K, Ohrlander S, Lingman G. Long-term ailments due to anal sphincter rupture caused by delivery - a hidden problem. Eur J Obstet Gynecol Reprod Biol 1988;27:27-32.

113. Fenner DE, Genberg B, Brahma P, Marek L, DeLancey JO. Fecal and urinary incontinence after vaginal delivery with anal sphincter disruption in an obstetrics unit in the United States. Am J Obstet Gynecol 2003;189:1543-49.

114. Fitzpatrick M, McQuillan K, O’Herlihy C. Influence of persistent occiput posterior position on delivery outcome. Obstet Gynecol 2001;98:1027-31.

115. Ali A, Glennon K, Kirkham C, Yousif S, Eogan M. Delivery outcomes and events in subsequent pregnancies after pre­vious anal sphincter injury. Eur J Obstet Gynecol Reprod Biol 2014;174:51-53.

116. Yogev Y, Hiersch L, Maresky L, Wasserberg N, Wiznitzer A, Melamed N. Third and fourth degree perineal tears - the risk of recurrence in subsequent pregnancy. J Matern Fetal Neonatal Med 2014;27:177-81.

117. Al-Mufti R, McCarthy A, Fisk NM. Obstetricians’ personal choice and mode of delivery. Lancet 1996;347:544.

118. Al-Mufti R, McCarthy A, Fisk NM. Survey of obstetricians’ per­sonal preference and discretionary practice. Eur J Obstet Gynecol Reprod Biol 1997;73:1-4.